Acute myeloid leukemia (AML) patients harboring the FLT3-ITD mutation are considered a high risk patient subset preferentially allocated for allogeneic stem cell transplantation in first remission. 
| I N TR ODU C TI ON
Acute myeloid leukemia (AML) patients harboring the fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation are a particularly clinically challenging patient segment in the field of hematologic malignancies. Nearly a third of AML patients with baseline normal cytogenetics present with FLT3-ITD which has consistently been shown to confer poor long term outcomes resulting from a remarkably high relapse rate.
1-8 Whereas the negative prognostic impact imparted by FLT3-ITD is unequivocal, an ongoing debate in the field revolves around the question of whether allogeneic stem cell transplantation can overcome the detrimental impact of FLT3-ITD. In contrast to earlier published data, 9 and notwithstanding the absence of randomized trials comparing transplantation with chemotherapy exclusive approaches, the bulk of current evidence suggests that allogeneic transplantation improves survival of FLT3-ITD mutated patients. 7, [10] [11] [12] [13] [14] [15] Haploidentical stem cell transplantation (haplo-SCT) presents a valid option for those patients in need of a timely allogeneic transplantation and lacking a fully matched HLA matched donor. The early experience with haplo-SCT was initially characterized by an increased incidence of transplant related mortality due to the slow kinetics of immune reconstitution leading to an increased incidence of fungal and viral infections as well as graft rejection. 16 However, significant advances in haplo-SCT have been recently realized with the introduction of novel immunosuppression modulation approaches, namely post-transplantation cyclophosphamide (PTCy) 17 and antithymocyte globulin (ATG) based protocols, 18 which via selective in-vivo depletion of donor T cells have achieved acceptable rates of engraftment, thus negating the need for profound T cell depletion. Indeed, the evolving application of haplo-SCT in AML is evident with recent publications indicating comparable clinical outcomes between these T cell replete haplo-SCT modalities and allogeneic transplantation from partially HLA mismatched (9/10) unrelated donors, and possibly HLA matched unrelated (10/10) donors and even HLA matched sibling donors. [19] [20] [21] [22] [23] [24] Hence, it is becoming imperative to characterize the impact of haplo-SCT on specific subsets of AML patients. As of yet, no formal evaluation of the impact of FLT3-ITD on outcomes following haplo-SCT has been performed. In this analysis of 293 AML patients, we set out to determine whether FLT3-ITD maintained its prognostic significance for AML patients undergoing T-cell replete haplo-HCT in first remission. in FLT3 wt patients. Additionally, most of the FLT3-ITD patients had a concomitant NPM1 mutation while the majority of FLT3-ITD wt patients did not have an NPM1 mutation (61% versus 10%; P 5 .0001). Conditioning intensity did not differ to a significant degree between FLT3-ITD mutated patients and FLT3 wt patients, whereas patients in the FLT3-ITD AML cohort received less frequently T-cell depletion with ATG and had a higher proportion of bone marrow used as the stem cell source. Details on the different conditioning regimens used for patients in this analysis are detailed in Supporting Information Table S1 .
| M E TH ODS

| Transplant outcomes
Neutrophil recovery rates at 30 days were not significantly different between FLT3-ITD and FLT3 wt patients with a 96% engraftment rate observed in both groups; P 5 .9. At 2 years, the overall incidence of relapse was 17% (95% CI: 12.6-22) with a 61% (95% CI: 55.1-67.4) rate of LFS.
The overall survival rate was 66% (95% CI: 60.8-72.8) whereas NRM was seen in 21% of the patients on this cohort (95% CI: 16.9-27). Grade II-IV acute GHVD was experienced by 29% (95% CI: 24-34.6) of the patients while chronic GVHD was diagnosed in 36% (95% CI: 30.1-42.4) of patients. Extensive chronic GVHD was seen in 11% of the patients (95% CI: 8.1-16.4). Supporting Information Table S2 outlines the main etiologies accounting for patient death in this analysis, with lethal infections and disease relapse being the leading causes for patient death.
| Impact of FLT3-ITD on clinical outcome
To determine whether FLT3-ITD impacted on clinical outcome, we initially performed a univariate analysis which is summarized in Supporting Information Table S5 summarizes the baseline characteristics of this patient cohort). As shown in the multivariate analysis presented in Supporting Information Table S6 , the rates of relapse, LFS, overall survival, and GRFS were not significantly different between all donor groups (haplo-SCT served as the reference group). Of note, patients transplanted from matched sibling donors did experience better NRM rates (HR 5 0.51, 95% CI, 0.28-0.92; P 5 .026) whereas patients transplanted from matched unrelated donors experienced inferior grade II-IV acute GVHD rates (HR 5 1.73, 95% CI, 1.04-2.87; P 5 .032).
| Impact of FLT3-ITD on outcome of patients with intermediate risk cytogenetics
Since most of the FLT3-ITD patients in our cohort harbored intermediate risk cytogenetics, we repeated our analysis focusing specifically on the 210 patients with intermediate risk cytogenetics. In this subgroup analysis, whose baseline data are summarized in Supporting Information Table S7 , patients not harboring the FLT3-ITD mutation were younger (39 versus 45; P 5 .023), and were less likely to receive PTCy compared to their FLT3-ITD mutated counterparts (38% versus 55%; P 5 .004). For this group of patients, the 2 year LFS and OS rates were 59% and 66%, respectively. Whereas relapse incidence and NRM rates were 17% and 28%, respectively. Grade II-IV acute GVHD was observed in 28% of patients and chronic GVHD was diagnosed in 36%.
As shown in Figure 2 , a univariate analysis followed by a multivariate analysis, summarized in Supporting Information Table S8 , confirmed Abbreviations: ATG, anti-thymocyte globulin; BM, bone marrow; GRFS, GVHD-free/relapse-free survival; GVHD, graft versus host disease; KPS, Karnofsky performance status; LFS, leukemia-free survival; MAC, myeloablative conditioning; NRM, nonrelapse mortality; OS, overall survival; PB, peripheral blood; PTCy, post-transplant cyclophosphamide; RI, relapse incidence; RIC, reduced intensity conditioining.
that also for this group of patients, the presence of a FLT3-ITD mutation also did not influence disease or transplant related outcomes.
| D I SCUSSION
Consequent to its high incidence and decidedly detrimental impact on patients, FLT3-ITD is considered the most important molecular determinant of outcome in AML patients. Thus, FLT3-ITD patients are referred to transplant early during the therapeutic sequence with the hope that allogeneic stem cell transplantation will mitigate some of the unfavorable clinical magnitude associated with FLT3-ITD. 27, 28 In this analysis we attempted to determine whether in AML patients patients undergoing allogeneic SCT in CR1, exemplified by two EBMT studies using different conditioning regimens. 14, 15 The emerging experience with haplo-SCT in AML is suggestive of a comparable degree of disease control with that of conventional stem cell sources, namely HLA matched sibling and unrelated donors. [19] [20] [21] [22] Yet, to date the impact of FLT3-ITD in the setting of haplo-SCT has not been rigorously investigated. Our data indicate that the lack of a prognostic effect of FLT3-ITD, findings which diverge from the results of the recent analysis published by Wang and colleagues, 22 where FLT3-ITD was found to be associated with a decreased 3 year disease free survival rate compared with non FLT3-ITD mutated patients (60% versus 79%). However, as most patients in that analysis did not have Several important limitations to our analysis merit acknowledgement. As our knowledge of the molecular workings of AML expands, it is becoming clearly established that gene-gene interactions profoundly impact on the outcome of AML patients, 37, 38 thus the presence of DNMT3A, IDH1, RUNX1, and additional modifying genes which were not captured in our registry may have contributed to our findings. The FLT3 allelic ratio is an additional prognostic component previously proposed to influence outcome of patients and which owing to the retrospective nature of our dataset was not analyzed by us. 30, 39, 40 Additionally, we recognize that the GVHD prophylaxis modalities used in this analysis, namely PTCy and ATG, were not equally distributed between FLT3-ITD mutated and nonmutated patients, with a larger proportion of FLT3-ITD patients receiving PTCy. Considering the abovementioned studies using PTCy in AML, we cannot completely exclude the possibility that this may have improved the outcome of the FLT3-ITD mutated patient subset. Lastly, minimal residual disease (MRD) is increasingly being used to determine the depth of remission prior to stem cell transplantation and would decidedly further inform our analysis. 41, 42 Taken together, the collective data in this analysis suggest that Tcell replete haploidentical transplantation may conceivably mitigate the deleterious impact associated with FLT3-ITD in AML. Indeed, haploidentical transplantation for AML patients in first remission is a feasible option with very good outcomes and should be performed without delay as outcomes beyond first remission are very poor. Possible implications of our data are that T-cell replete haplo-SCT may be a preferred therapeutic modality for this specific high risk subset of patients, a hypothesis that would need to be rigorously confirmed in randomized fashion.
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